I have heard DK say that he is confident that this will get the CE mark.
He also said it was imminent.
Why is he confident?
Is this because the company has fulfilled the previous requests of the BSI?
Does anybody know what these requests were?
Is it because Directors initially expected 4-5 resections (10%) heading into the study and it was 24%?
Is this a significant improvement on alternatives?
If CE mark doesnt get approved, we may as well forget FDA, right?
I have heard DK say that he is confident that this will get the...
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
-0.001(12.5%) |
Mkt cap ! $49.19M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.8¢ | 0.7¢ | $69.42K | 8.685M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 67 | 28673846 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 7597003 | 11 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| OSL (ASX) Chart |
